Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Non Hodgkin Lymphoma
Interventions
DRUG

Fludarabine Phosphate (Fludara)

All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.

Trial Locations (14)

16132

Genova

33100

Udine

40138

Bologna

47023

Cesena

47100

Forlì

47900

Rimini

48100

Ravenna

50139

Florence

53100

Siena

80131

Napoli

00144

Roma

00168

Roma

09121

Cagliari

00161

Roma

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00185445 - Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL | Biotech Hunter | Biotech Hunter